Recce’s anti-infective topical gel fights hard against tough antibiotic-resistant burn wounds

• Recce’s R327G highly effective against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa infected wounds (in-vivo)
• R327G efficacy outcomes statistically significant and consistently superior to comparator antibiotic Soframycin
• R327G also demonstrated statistically significant wound healing/wound contraction over treatment period

Special Report: New data shows Recce Pharmaceuticals’ synthetic anti-infective RECCE 327 topical gel (R327G) is highly effective against two of the most challenging antibiotic-resistant bacteria affecting burn wounds.

Recce Pharmaceuticals (ASX:RCE) has announced positive results from recent in-vivo studies using rat infection models of R327G in treating methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa (P. aeruginosa).

MRSA and P. aeruginosa are included in the World Health Organization’s list of drug-resistant bacteria most threatening to human health and are the most common bacteria isolated from chronic wounds.

In the study R327G delivered statistically significant reductions in bacterial load compared to untreated control groups.

Bacterial counts were substantially reduced by day four and by day eight – the gel achieved up to a 99.9% reduction in MRSA and a 99.99% reduction in P. aeruginosa, highlighting its potent antimicrobial capabilities.

R327G also consistently exceeded Soframycin, a standard comparator antibiotic used in topical wound care.

Accelerated wound healing

Beyond killing bacteria, Recce said R327G also showed accelerated wound healing.

The study recorded statistically significant improvements in wound contraction compared to both untreated wounds and those treated with Soframycin.

The gel was well tolerated with no adverse effects observed in treated animals.

In the study, R327G was applied once daily to infected burn wounds over a seven-day treatment period. Soframycin was applied twice daily per its optimal treatment frequency.

Recce said the potential to have a once-daily R327G treatment instead of twice-daily Soframycin indicates advantages to patients, clinicians and the pharmacoeconomic model.

Watch: Managing director and CEO James Graham joins Stockhead TV

Results support collaboration with US Department of Defense

The results further validate the therapeutic potential of R327G as a topical treatment option for infected wounds, including burns, with its development supported through an ongoing collaboration with the US Department of Defense (DoD).

The study is part of Recce’s broader burn wound program, backed by a US$2 million grant and a Cooperative Research and Development Agreement (CRADA) with the US Army Medical Research Institute of Infectious Diseases (USAMRIID).

“These outstanding results represent a further step forward for our US DoD burn wound program,” CEO James Graham said.

“R327G not only demonstrated superior antimicrobial performance but also promoted significantly faster healing of burn wounds.

“We look forward to progressing R327G further to deliver an urgently needed solution to patients suffering from these unmet medical needs.”

This article was developed in collaboration with Recce Pharmaceuticals, a Stockhead advertiser at the time of publishing.

This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.